Medexus Pharmaceuticals Inc. (TSE:MDP - Free Report) - Research analysts at Raymond James issued their FY2029 EPS estimates for Medexus Pharmaceuticals in a research report issued to clients and investors on Tuesday, November 19th. Raymond James analyst R. Sarugaser forecasts that the company will post earnings per share of $0.89 for the year. Raymond James has a "Outperform" rating and a $4.00 price objective on the stock. The consensus estimate for Medexus Pharmaceuticals' current full-year earnings is $0.16 per share.
Other equities analysts have also issued reports about the company. Stifel Canada upgraded Medexus Pharmaceuticals from a "moderate buy" rating to a "strong-buy" rating in a research report on Monday, August 12th. Leede Financial set a C$8.25 price target on Medexus Pharmaceuticals and gave the company a "speculative buy" rating in a research note on Monday, September 30th. Finally, Stifel Nicolaus increased their price objective on Medexus Pharmaceuticals from C$3.00 to C$3.50 and gave the stock a "buy" rating in a report on Thursday, August 22nd. Three investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of C$5.25.
Read Our Latest Research Report on MDP
Medexus Pharmaceuticals Price Performance
Shares of Medexus Pharmaceuticals stock traded down C$0.02 during trading hours on Thursday, hitting C$2.13. The company's stock had a trading volume of 31,229 shares, compared to its average volume of 41,537. The company has a market capitalization of C$52.25 million, a PE ratio of 43.20 and a beta of 1.96. The stock has a 50 day moving average of C$2.47 and a 200 day moving average of C$2.19. Medexus Pharmaceuticals has a 12 month low of C$1.44 and a 12 month high of C$3.16.
About Medexus Pharmaceuticals
(
Get Free Report)
Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.
Read More
Before you consider Medexus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medexus Pharmaceuticals wasn't on the list.
While Medexus Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
